We are proud to share the interview recently published by 24/7 Biopharma (Issue 01, March 2026), with our colleague Roberto Fanelli, Catalogue APIs Business Unit Leader.
In the feature, Roberto Fanelli addresses the evolving regulatory and scientific landscape surrounding nitrosamine impurities, outlining Dipharma’s proactive approach to risk assessment, analytical investigation, and process mitigation strategies.
Among the technical highlights featured in the article is Dipharma’s ¹⁵N-NMR approach, further strengthening the understanding and control of complex nitrosamine-related risks.
Read the full interview here: https://247biopharma.com/issue12026/68/
To explore this topic in greater detail:
– Download our white paper on nitrosamine risk control available here, on our website
– Read the scientific article (open access): https://pubs.acs.org/doi/10.1021/acs.oprd.5c00223
We sincerely thank 24/7 Biopharma for the opportunity to showcase our expertise on this important and highly relevant topic.
To learn more about Dipharma’s know-how and capabilities, get in touch with us.
For more information
Paola Clerici
Communication Manager
DIPHARMA FRANCIS S.r.l.
paola.clerici@dipharma.com
